

Available online at www.sciencedirect.com



Bioorganic & Medicinal Chemistry Letters

Bioorganic & Medicinal Chemistry Letters 14 (2004) 5971-5974

Development of a new class of potential antiatherosclerosis agents: NO-donor antioxidants

Clara Cena,^a Donatella Boschi,^a Gian Cesare Tron,^b Kostantin Chegaev,^a Loretta Lazzarato,^a Antonella Di Stilo,^a Manuela Aragno,^c Roberta Fruttero^a and Alberto Gasco^{a,*}

^aDipartimento di Scienza e Tecnologia del Farmaco, Via P. Giuria 9, I-10125 Torino, Italy ^bDipartimento di Scienze Chimiche, Alimentari, Farmaceutiche e Farmacologiche, Via Bovio 6, I-28100 Novara, Italy ^cDipartimento di Medicina e Oncologia Sperimentale, C.so Raffaello 30, I-10125 Torino, Italy

> Received 18 June 2004; revised 1 September 2004; accepted 4 October 2004 Available online 22 October 2004

Abstract—A new class of NO-donor phenol derivatives is described. The products were obtained by joining appropriate phenols with either nitrooxy or 3-phenylsulfonylfuroxan-4-yloxy moieties. All the compounds proved to inhibit the ferrous salt/ascorbate induced lipidic peroxidation of membrane lipids of rat hepatocytes. They were also capable of dilating rat aorta strips precontracted with phenylephrine.

© 2004 Elsevier Ltd. All rights reserved.

1. Introduction

Atherosclerosis is the main cause of morbidity and mortality in the western societies.¹ This pathology is closely correlated with endothelial dysfunction resulting from an increase of plasma lipids, peroxidation of low-density lipoproteins (LDLs) and an impairment of endothelialderived relaxing factor (EDRF, nitric oxide, NO')-mediated bioactions. Oxidative modifications of high levels of LDLs following oxidative stress, lead to the formation of foam cells, precursors of atherosclerotic plaques. Experimental evidence supports the hypothesis that the treatment of hypercholesterolemic animals and human subjects with appropriate amounts of antioxidants can reduce the LDL oxidation and the expression of atherosclerosis.^{1,2} In an atherosclerotic blood vessel, NO[•] bioactions are impaired by a number of reasons including a possible decreased NO[•] production, an increased NO[•] inactivation and a decrease in responsiveness of the target cells to NO. By contrast, vasodilation to exogenous sources of NO[•] seems to be preserved.³ On these bases we have recently designed a large series of hybrid structures in which a number of selected antioxidants were linked to NO-donor moieties through appropriate spacers. Here we report the preliminary results of a study on the capacity of inhibiting the ferrous salt/ascorbate induced lipid peroxidation of membrane lipids of rat hepatocytes and on the in vitro vasodilating properties of a first series of such products. As NO-donor moieties, we chose either the nitrooxy function present in simple vasodilating nitric esters 1 (der.s 17, 20, 24) or the 3-phenylsulfonylfuroxan-4-yloxy moiety present in 4-ethoxy-3phenylsulfonylfuroxan (CHF 2363) 2, a known NOdependent vasodilator⁴ (der.s 10, 11, 15). As antioxidants, we considered phenols characterized by having different O-H bond dissociation energy (BDE), which is one of the factors that contribute to the antioxidant capacity of the products: *p*-cresol (**25**, BDE, 86.2 ± 0.6 kcal/mol), 2,6-di-*t*-butyl-*p*-methylphenol (**26**, BDE, 81.02 ± 0.13 kcal/mol) and 6-hydroxy-2,2,5,7,8pentamethylchroman, the phenol substructure present in the vitamin E (27, BDE, 78.2 \pm 0.18 kcal/mol).⁵

2. Chemistry

The preparation of the furoxan derivatives follows the synthetic routes that are illustrated in Scheme $1.^6$ The hydroxyl groups of the *p*-hydroxybenzaldehyde (3) and of its 2,3-di-*t*-butyl derivative 4 were protected with

Keywords: Phenol antioxidants; Nitric oxide; NO donors; NO-donor phenol antioxidants.

^{*} Corresponding author. Tel.: +39 011 6707670; fax: +39 011 6707286; e-mail: alberto.gasco@unito.it

⁰⁹⁶⁰⁻⁸⁹⁴X/\$ - see front matter @ 2004 Elsevier Ltd. All rights reserved. doi:10.1016/j.bmcl.2004.10.006



Scheme 1. Reagents and conditions: (i) 3, TBDMSCl, NaH, THF; 4, MEMCl, di-*iso*-propyl ethylamine, $C_2H_4Cl_2$, reflux; (ii) (EtO)₂POCH₂-COOEt/*t*-BuOK, THF, -78 °C; (iii) H₂, Pd/C, EtOH; (iv) LiAlH₄, THF; (v) 9, NaH, THF; (vi) HCl/dioxane to obtain 10, TFA/CH₂Cl₂ to obtain 11 and 15; (vii) *p*-TSA, EtOH, reflux; (viii) MEMCl, NaH, THF.

t-butyldimethylsilyl chloride (TBDMSCl) and 2-methoxyethoxymethyl chloride (MEMCl), respectively. The resulting products were subjected to the modified Wittig reaction in the presence of the phosphonacetic acid triethyl ester in basic medium to obtain the α,β -unsaturated esters 5 and 6, respectively. Both the products were transformed into the corresponding saturated alcohols 7 and 8 by reduction first with H₂, Pd/C and then with LiAlH₄. Selective nucleophilic displacement of the 4-phenylsulfonyl group of the 3,4-bis(phenylsulfonyl)furoxan (9) by the intermediates 7 and 8 in dry THF in the presence of NaH followed by acid deprotection of the phenol functions afforded the final products 10, 11. The starting material for the preparation of the furoxan 15 was the commercial acid 12. This product was treated with ethanol in the presence of *p*-toluenesulfonic acid (*p*-TSA) to obtain the corresponding ester that was MEM protected on the hydroxy group to afford 13. This latter compound was reduced with LiAlH₄ in dry THF to the corresponding alcohol 14 and then left to react with 9 in basic medium to give, after deprotection of the phenol function, the final product 15.

Nitrooxy derivatives were synthesized according to the pathway reported in Scheme 2.⁷ The simple nitrooxy derivative **17** was obtained by the action of AgNO₃ on 4-(3-bromopropyl)phenol (**16**) in acetonitrile at 60 °C. To prepare the final product **20**, the alcoholic group of



Scheme 2. Reagents and conditions: (i) AgNO₃, CH₃CN, 60°C; (ii) TsCl, TEA, CH₂Cl₂, rt; (iii) (*t*-Boc)₂O, DMAP, CH₂Cl₂, rt; (iv) Bu₄NNO₃, benzene, reflux; (v) TFA, CH₂Cl₂, rt; (vi) allyl bromide, NaH, DMF, rt; (vii) a. 9-BBN, THF, rt, b. H₂O₂, NaOAc, 0°C.

18 was treated with *p*-toluenesulfonyl chloride (TsCl) in the presence of triethylamine (TEA). The corresponding tosylate, obtained in fair yield, was later protected on the phenol group with di-t-butyl dicarbonate $(t-Boc)_2O$, in the presence of 4-N,N-dimethylaminopyridine (DMAP) to give 19. This latter product was treated in refluxing benzene with tetrabutylammonium nitrate (Bu₄NNO₃) and then at room temperature with a CH₂Cl₂ solution of trifluoroacetic acid to afford the final compound **20**. The MEM protected 6-hydroxychroman structure 14 was used as a starting material for the preparation of 24. It was transformed into 21 by reaction with allyl bromide and NaH in N,N-dimethylformamide (DMF). This latter product was left to react first with 9-borabicyclo[3.3.1]nonane (9-BBN) in THF and then with hydrogen peroxide and sodium acetate to give the propanol derivative 22. The corresponding tosylate 23, obtained under the same conditions used to prepare the tosylate of 18, was transformed into the final nitrooxyderivative 24 following procedures similar to those used to transform 19 into 20.

3. Results and discussion

All the products described in the present work were assessed as inhibitors of ferrous salt/ascorbate induced lipidic peroxidation of membrane lipids of rat hepatocytes.⁸ The progress of the peroxidation was followed by visible spectroscopy detection of 2-thiobarbituric acid reactive substances (TBARS), which are the final metabolites of the autooxidation. All the products were able to inhibit the lipid oxidation in a dose dependent manner. One example is reported in Figure 1.

The potencies as antioxidants of these compounds (IC₅₀) are collected in Table 1 together with those of the parent phenols. The hybrid products show potencies near to those of the reference phenols, with the only partial exception of the derivative **10**. It is noteworthy that also the NO-donor furoxan **2** displays an antioxidant action, which is close to that of **25**.

SUPEL 0.50μm 0 10 - 0.75μm 0 10 - 0.75μm 0 10 20 30

time (min)

20

Figure 1. Effect of 15 on time course of lipid peroxidation.

The potential antioxidant activity of furoxan derivatives is an interesting aspect of the furoxan chemistry that is worthy of additional investigation.

All the hybrid products behaved as potent in vitro vasodilators. They were capable of dilating in a dose dependent manner rat aorta strips precontracted with phenylephrine.⁹ One example is reported in Figure 2.

The vasodilating potencies (EC_{50}) of all the compounds are collected in Table 1. This action is cyclic GMP (cGMP) dependent since a considerable decrease in the potency was observed when the experiments were repeated in the presence of 1*H*-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ), a well known inhibitor of the sGC.¹⁰ A comparison between the IC_{50} and EC_{50} values shows that in this series of products the vasodilating action prevails over the antioxidant one. Also the nitrooxy derivatives proved to be dose dependent antioxidants with a potency similar to that of the reference phenols (Table 1). They too display in vitro sGC dependent vasodilating activity but it is less potent than the corresponding furoxan derivatives' activity (Table 1). Work is in progress in order to obtain products with better balanced antioxidant and vasodilating activities. All the products reported in this preliminary paper could be

-10.0 -7.5 -5.0 -2.5 log conc (M) Figure 2. Concentration-response curves for vasodilating activity of compound 15 in the absence (open circle) and in the presence (solid

Table 1. Antioxidant and vasodilating activity of the reference NO-donors 1-2, of the hybrids 10, 11, 15, 17, 20, 24 and of the parent phenols 25-27

circle) of ODQ.

Compd	Antioxidant activity IC_{50} (95% CL), μM^a	Vasodilating activity	
		$EC_{50} \pm SE, \ \mu M^a$	+ODQ EC ₅₀ ± SE, μM
1 (R = n - pr)	b	41 ± 6	с
2	110 (98–122)	0.012 ± 0.002	1.2 ± 0.2
10	47 (45–48)	0.012 ± 0.001	0.36 ± 0.09
11	2.0 (1.9–2.0)	0.11 ± 0.03	4.8 ± 0.5
15	0.49 (0.48-0.50)	0.044 ± 0.004	0.67 ± 0.09
17	143 (133–153)	1.0 ± 0.2	с
20	2.0 (1.9–2.1)	40 ± 1	с
24	0.15 (0.15-0.16)	1.2 ± 0.1	10 ± 1
25	290 (260–324)	_	
26	1.7 (1.6–1.9)	_	
27	0.17 (0.16-0.17)	_	

^a Values are means of at least five experiments.

^b Derivative 1 was inactive when tested at 1 mM.

^c The products 1, 17 and 20 induced, respectively, $4.6 \pm 0.6\%$, $38 \pm 9\%$, $15 \pm 5\%$ of vasodilation when tested at $100 \,\mu$ M.



of value as potential antiatherosclerotic agents and they are worthy of in vivo further investigations.

Acknowledgements

This study was supported by a MIUR grant.

References and notes

- 1. Eberhardt, M. K. *Reactive Oxygen Metabolites*; CRC: BocaRaton, 2000.
- 2. Keaney, J. F.; Vita, J. A. Prog. Cardiovasc. Dis. 1995, 38, 129.
- 3. Dillon, G. A.; Vita, J. A. In *Nitric Oxide and the Cardiovascular System*; Loscalzo, J., Vita, A. J., Eds.; Humana: Totowa, 2000; pp 207–226.
- Civelli, M.; Giossi, M.; Caruso, P.; Razzetti, R.; Bergamaschi, M.; Bongrani, S.; Gasco, A. *Br. J. Pharmacol.* 1996, *118*, 923–928.
- 5. Luccarini, M.; Pedrielli, P.; Pedulli, G. F.; Cabiddu, S.; Fattuoni, C. J. Org. Chem. **1996**, *61*, 9259–9263.
- 6. Compound 10: mp 92–93 °C (EtOH); *m*/*z* (EI): 376 (M⁺); ¹H NMR (DMSO- d_6): δ 9.19 (s, 1H, OH), 8.05–8.03 (m, 2H), 7.93-7.88 (m, 1H), 7.78-7.73 (m, 2H) (PhSO₂), 7.00-6.98 (m, 2H), 6.70-6.67 (m, 2H) (PhOH), 4.34 (t, 2H, $J = 6.2 \text{ Hz}, \text{ CH}_2\text{O}$), 2.57 (t, 2H, $J = 7.5 \text{ Hz}, \text{ CH}_2\text{Ph}$), 2.00 (m, 2H, CH₂CH₂CH₂). Anal. (C₁₉H₂₀N₂O₈S) C, H, N. *Compound* **11**: mp 110–111 °C (EtOH); *m/z* (EI): 488 (M⁺); ¹H NMR (DMSO- d_6): δ 8.05–8.02 (m, 2H), 7.89–7.86 (m, 1H), 7.77-7.72 (m, 2H) (PhSO₂), 6.86 (s, 2H, PhOH), 6.74 (s, 1H, OH), 4.33 (t, 2H, J = 5.9 Hz, CH₂O), 2.57 (t, 2H, $J = 7.2 \text{ Hz}, \text{ CH}_2\text{Ph}$), 1.99 (m, 2H, CH₂CH₂CH₂), 1.33 (s, 18H, t-Bu). Anal. (C₂₅H₃₂N₂O₆S) C, H, N. Compound 15: mp 68–72 °C dec (MeOH/H₂O); m/z (EI): 460 (M⁺); ¹H NMR (CDCl₃): δ 8.00-7.98 (m, 2H), 7.72-7.68 (m, 1H), 7.53-7.48 (m, 2H) (PhSO₂), 4.46 (1H, d, AB system, J = 10.4 Hz, CH_aH_bO), 4.40 (1H, d, AB system, $J = 10.4 \text{ Hz}, \text{ CH}_{a}H_{b}\text{O}), 2.71 \text{ (m, 2H, 4-CH}_{2}\text{-chromane}),$ 1.94-1.87 (m, 1H), 1.28-1.22 (m, 1H) (3-CH₂-chromane), 2.16 (s, 3H), 2.14 (s, 3H), 2.02 (s, 3H) (5,7,8-CH₃-chromane), 1.41 (s, 3H, 2-CH₃-chromane). Anal. (C₂₂H₂₄N₂O₇S) C, H, N.
- Compound 17: oil; m/z (EI): 197 (M⁺); ¹H NMR (CDCl₃): δ
 7.05–7.02 (m, 2H, Ph), 6.80–6.78 (m, 2H, Ph), 5.92 (br, 1H, OH), 4.42 (t, 2H, J = 6.5Hz, CH₂O), 2.65 (t, 2H, J = 8.0 Hz, CH₂Ph), 2.04–1.95 (m, 2H, CH₂CH₂CH₂O). Anal. (C₉H₁NO₄) C, H, N. Compound 20: mp 78–79°C;

m/*z* (EI): 309 (M⁺); ¹H NMR (CDCl₃): δ 6.96 (s, 2H, Ph), 5.10 (s, 1H, OH), 4.47 (t, 2H, J = 6.5Hz, CH₂O), 2.65 (t, 2H, J = 7.7Hz, CH₂Ph), 2.06–2.00 (m, 2H, CH₂CH₂CH₂O), 1.43 (s, 18H, *t*-Bu). Anal. (C₁₇H₂₇NO₄) C, H, N. *Compound* **24**: oil; *m*/*z* (EI): 339 (M⁺); ¹H NMR (CDCl₃): δ 4.57 (t, 2H, J = 6.5Hz, CH₂ONO₂), 4.19 (s, 1H, OH), 3.63–3.58 (m, 2H, OCH₂CH₂), 3.47 (1H, d, AB system, J = 9.8Hz, CH_aH_bO), 3.41 (1H, d, AB system, J = 9.8Hz, CH_aH_bO), 2.61 (m, 2H, 4-CH₂-chromane), 2.15 (s, 3H), 2.11 (s, 3H), 2.09 (s, 3H) (5,7,8-CH₃-chromane), 2.03–1.92 (m, 3H) (3-CH*H*-chromane), 1.57 (s, 3H, 2-CH₃-chromane). Anal. (C₁₇H₂₅NO₆) C, H, N.

- 8. Microsomal membranes from male Wistar rats (200–250 g) were prepared by differential centrifugation (8000g, 20 min; 120,000g, 1 h) in a HEPES/sucrose buffer (10 mM, 250 mM, pH = 7.4) and stored at $-80 \degree$ C. Incubation was performed at 37°C in a Tris-HCl/KCl buffer (100 mM, 150 mM, pH = 7.4) containing microsomal membranes (2mg prot/mL), ascorbic acid (100 µM) and DMSO solutions of the tested compounds. Addition of DMSO alone (maximal amount 5%) did not change significantly the extent of peroxidation in the control experiments. Lipid peroxidation was initiated by adding $FeSO_4$ 2.5 $\mu M.$ Aliquots were taken from the incubation mixture at 5, 15 and 30 min and treated with trichloroacetic acid (TCA) 10% p/v. Lipid peroxidation was assessed by spectrophotometric (543nm) determination of the TBARS consisting mainly of malondialdehyde (MDA), and TBARS concentrations (expressed in nmol/ mg protein) were obtained by interpolation with a MDA standard curve.¹¹ The antioxidant activity of tested compounds was evaluated as the % of inhibition of TBARS production with respect to control samples, using the plateau values obtained after 30 min of incubation. IC₅₀ values were calculated by non linear regression analysis.
- 9. The experiments were assessed according to the procedure described in *J. Med. Chem.* **1997**, *40*, 463–469 with little modification: the aortic strips were contracted with $1 \mu M$ L-phenylephrine; the effect of $1 \mu M$ ODQ on relaxation was evaluated in a separate series of experiments in which it was added to the bath at least 5 min before the contraction; responses were recorded by isometric transducer connected to the MacLab System PowerLab.
- Schrammel, A.; Behrends, S.; Schmidt, K.; Koesling, D.; Mayer, B. Mol. Pharmacol. 1996, 50, 1–5.
- Mastrocola, R.; Aragno, M.; Betteto, S.; Brignardello, E.; Catalano, M. G.; Danni, O.; Boccuzzi, G. *Life Sci.* 2003, 73, 289–299.